Skip to main content
. 2023 Jul 24;160:31. doi: 10.1186/s41065-023-00293-w

Table 1.

Clinical characteristics of LUAD patients in the testing and training groups

Covariates Type Total n(%) Group n(%) P-value
Testing Training
Age (years)  <  = 65 232(47.06%) 120(48.78%) 112(45.34%) 0.5527
 > 65 251(50.91%) 122(49.59%) 129(52.23%)
unknow 10(2.03%) 4(1.63%) 6(2.43%)
Gender female 264(53.55%) 130(52.85%) 134(54.25%) 0.8239
male 229(46.45%) 116(47.15%) 113(45.75%)
Tumor Stage I 265(53.75%) 134(54.47%) 131(53.04%) 0.8863
II 116(23.53%) 60(24.39%) 56(22.67%)
III 79(16.02%) 38(15.45%) 41(16.6%)
IV 25(5.07%) 11(4.47%) 14(5.67%)
unknow 8(1.62%) 3(1.22%) 5(2.02%)
Stage
 T T1 164(33.27%) 71(28.86%) 93(37.65%) 0.1079
T2 265(53.75%) 143(58.13%) 122(49.39%)
T3 43(8.72%) 19(7.72%) 24(9.72%)
T4 18(3.65%) 11(4.47%) 7(2.83%)
unknow 3(0.61%) 2(0.81%) 1(0.4%)
 M M0 327(66.33%) 159(64.63%) 168(68.02%) 0.9582
M1 24(4.87%) 11(4.47%) 13(5.26%)
unknow 142(28.8%) 76(30.89%) 66(26.72%)
 N N0 319(64.71%) 161(65.45%) 158(63.97%) 0.3212
N1 93(18.86%) 50(20.33%) 43(17.41%)
N2 68(13.79%) 30(12.2%) 38(15.38%)
N3 2(0.41%) 0(0%) 2(0.81%)
unknow 11(2.23%) 5(2.03%) 6(2.43%)